No Data
Morgan Stanley Maintains Personalis(PSNL.US) With Hold Rating, Maintains Target Price $5
Morgan Stanley Maintains Personalis(PSNL.US) With Hold Rating, Raises Target Price to $5
Personalis: Promising Growth in Biopharma Sales Amidst Strategic Challenges – Hold Rating Maintained
Cathie Wood's ARK Investment Bought 266.8K Shares of Personalis Today
Here's Why We're Not Too Worried About Personalis' (NASDAQ:PSNL) Cash Burn Situation
Personalis Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags